Association between exposure to statins and AMD: adjusted models and dose-response relation
| Cases (n = 18007) | Controls (n = 86169) | Univariate odds ratio (95% CI) | Odds ratio adjusted for consultation rate (95% CI) | Final adjusted odds ratio (95% CI)* | p Value | |||
|---|---|---|---|---|---|---|---|---|
| *Adjusted for all potential confounders significantly associated with both AMD and statin use (that is, consultation rate (quintiles), smoking, alcohol intake, BMI, atherosclerosis, hyperlipidaemia, heart failure, diabetes, hypertension, cardiovascular drug use (excluding aspirin or statin), fibrate use). People with missing data are included as separate strata. | ||||||||
| †p value for trend. | ||||||||
| Statins | ||||||||
| Never | 17632 | (97.9%) | 84751 | (98.4%) | ||||
| Ever | 375 | (2.1%) | 1418 | (1.6%) | 1.32 (1.17–1.48) | 1.05 (0.93–1.19) | 0.93 (0.81–1.07) | 0.33 |
| Within 6 months of index date | 323 | (1.8%) | 1212 | (1.4%) | 1.32 (1.16–1.50) | 1.06 (0.93–1.21) | 0.95 (0.82–1.10) | 0.50 |
| Number of prescriptions (tertiles) | ||||||||
| 0 | 17632 | (97.9%) | 84751 | (98.4%) | Baseline | 0.27† | ||
| 1–6 | 125 | (0.7%) | 490 | (0.6%) | 1.26 (1.04–1.54) | 1.02 (0.84–1.25) | 0.91 (0.74–1.12) | |
| 7–19 | 141 | (0.8%) | 478 | (0.6%) | 1.47 (1.21–1.78) | 1.18 (0.97–1.43) | 1.05 (0.85–1.29) | |
| 20+ | 109 | (0.6%) | 450 | (0.5%) | 1.20 (0.97–1.49) | 0.96 (0.77–1.19) | 0.83 (0.66–1.05) | |
| Daily dose | ||||||||
| Never | 17632 | (97.9%) | 84751 | (98.4%) | Baseline | 0. 37† | ||
| 10 mg | 265 | (1.5%) | 993 | (1.2%) | 1.33 (1.15–1.53) | 1.07 (0.93–1.23) | 0.94 (0.80–1.10) | |
| 20 mg | 95 | (0.5%) | 370 | (0.4%) | 1.27 (1.01–1.60) | 1.01 (0.80–1.27) | 0.90 (0.70–1.14) | |
| 30–40 mg | 15 | (0.1%) | 55 | (0.1%) | 1.39 (0.78–2.47) | 1.11 (0.62–1.99) | 1.05 (0.58–1.89) | |